Literature DB >> 8302413

Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.

I Hisatome1, Y Tanaka, H Kotake, H Kosaka, N Hirata, Y Fujimoto, A Yoshida, C Shigemasa, H Mashiba, R Sato.   

Abstract

We encountered a case of hypouricemia with increases both in urate clearance (Cur) and in the ratio of Cur to creatinine clearance (Cur/Ccr), the normal daily urinary excretion of urate, and urolithiasis. Pyrazinamide markedly decreased Cur and Cur/Ccr, and both probenecid and benzbromarone markedly increased Cur and Cur/Ccr, however, benzbromarone did not increase either Cur or Cur/Ccr under pretreatment with pyrazinamide in the patient. Thus, the diagnosis was made of renal hypouricemia due to enhanced tubular secretion of urate. The urinary pH of the patient tended to be acidic. Three months after the start of alkalization of the patient's urine by K+, Na(+)-citrate, both urolithiasis and the symptoms related to urolithiasis disappeared. These results suggest that renal hypouricemia due to enhanced tubular secretion of urate can result in urolithiasis and the alkalization of urine may be an effective treatment for uric acid stones.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8302413     DOI: 10.1159/000187567

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

1.  Mutational analysis of idiopathic renal hypouricemia in Korea.

Authors:  Hae Il Cheong; Ju Hyung Kang; Joo Hoon Lee; Il Soo Ha; Suhnggwon Kim; Fusako Komoda; Takashi Sekine; Takashi Igarashi; Yong Choi
Journal:  Pediatr Nephrol       Date:  2005-05-24       Impact factor: 3.714

Review 2.  Hypouricemia: what the practicing rheumatologist should know about this condition.

Authors:  Carlos Pineda; Carina Soto-Fajardo; Jaime Mendoza; Jessica Gutiérrez; Hugo Sandoval
Journal:  Clin Rheumatol       Date:  2019-10-24       Impact factor: 2.980

Review 3.  The genetic framework for development of nephrolithiasis.

Authors:  Vinaya Vasudevan; Patrick Samson; Arthur D Smith; Zeph Okeke
Journal:  Asian J Urol       Date:  2016-11-28

4.  Xanthine urolithiasis: Inhibitors of xanthine crystallization.

Authors:  Felix Grases; Antonia Costa-Bauza; Joan Roig; Adrian Rodriguez
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

5.  Non-urate transporter 1, non-glucose transporter member 9-related renal hypouricemia and acute renal failure accompanied by hyperbilirubinemia after anaerobic exercise: a case report.

Authors:  Yoshitaka Furuto; Mariko Kawamura; Akio Namikawa; Hiroko Takahashi; Yuko Shibuya; Takayasu Mori; Eisei Sohara
Journal:  BMC Nephrol       Date:  2019-11-26       Impact factor: 2.388

Review 6.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31

7.  Transplantation of a kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report.

Authors:  Kiyokazu Tsuji; Mineaki Kitamura; Kumiko Muta; Yasushi Mochizuki; Takayasu Mori; Eisei Sohara; Shinichi Uchida; Hideki Sakai; Hiroshi Mukae; Tomoya Nishino
Journal:  BMC Nephrol       Date:  2020-07-16       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.